Dual specificity antibodies and methods of making and using
CA 2411374 C · Owner: Abbvie Inc. · Inventors: Kaymakcalan, Zehra; Collinson, Albert; Avgerinos, George
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be for example, entirely human , antibodies recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1.alpha. and IL-1.beta. and neutralize IL-1.alpha. and IL-1.beta. activity in vitroand in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions of the invention are , useful for detecting two different but structurally related antigens (e.g. IL- …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 28, 2001 and granted October 30, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 28, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 28, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.